These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26145167)

  • 1. Antibody fusions with immunomodulatory proteins for cancer therapy.
    Müller D
    Pharmacol Ther; 2015 Oct; 154():57-66. PubMed ID: 26145167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
    Müller D
    BioDrugs; 2014 Apr; 28(2):123-31. PubMed ID: 24018469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-cytokine fusion proteins.
    Kontermann RE
    Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytokines: a novel class of potent armed antibodies.
    Pasche N; Neri D
    Drug Discov Today; 2012 Jun; 17(11-12):583-90. PubMed ID: 22289353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
    Young PA; Morrison SL; Timmerman JM
    Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The present and future of immunocytokines for cancer treatment.
    Gout DY; Groen LS; van Egmond M
    Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytokines for cancer treatment: past, present and future.
    Neri D; Sondel PM
    Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Armed antibodies for cancer treatment: a promising tool in a changing era.
    Danielli R; Patuzzo R; Ruffini PA; Maurichi A; Giovannoni L; Elia G; Neri D; Santinami M
    Cancer Immunol Immunother; 2015 Jan; 64(1):113-21. PubMed ID: 25314912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.
    Valedkarimi Z; Nasiri H; Aghebati-Maleki L; Majidi J
    Biomed Pharmacother; 2017 Nov; 95():731-742. PubMed ID: 28888210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
    Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
    Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New era of tumor immunotherapy].
    Yoshitake Y; Nakatsura T; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody-cytokine fusion proteins for the therapy of cancer.
    Helguera G; Penichet ML
    Methods Mol Med; 2005; 109():347-74. PubMed ID: 15585931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
    Reisfeld RA; Gillies SD
    J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.